Astellas offloads once core fermentation assets to Taiho
This article was originally published in Scrip
Executive Summary
Astellas is bidding farewell to one of its former core areas of expertise with the decision to end in-house research activities in the fermentation area and divest most of its assets in the field to Taiho Pharmaceutical.